Company

Walden Biosciences, Inc.

Walden Biosciences develops therapies for chronic kidney disease.

About

Founded in 2020 and based in Cambridge, Walden Biosciences develops therapies targeting kidney diseases, including chronic kidney disease. Its pipeline includes CKD WAL0921 and CKD WAL0623. In October 2020, it raised USD 51 mn in Series A funding co-led by ARCH Venture Partners and UCB Ventures.

1Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in